G. Guyatt, J. Cairns, and D. Churchill, Evidence-Based Medicine, JAMA, vol.268, issue.17, pp.2420-2425, 1992.
DOI : 10.1001/jama.1992.03490170092032

D. Sackett, W. Rosenberg, J. Gray, R. Haynes, and W. Richardson, Evidence based medicine: what it is and what it isn't, BMJ, vol.312, issue.7023, pp.71-73, 1996.
DOI : 10.1136/bmj.312.7023.71

D. Grahame-smith, Evidence based medicine: Socratic dissent, BMJ, vol.310, issue.6987, pp.1126-1133, 1995.
DOI : 10.1136/bmj.310.6987.1126

G. Bouvenot and M. Vray, Essais cliniques : théorie, pratique et critique 4e édition revue et augmentée

D. Rennie, How to report randomized controlled trials. The CONSORT statement, JAMA: The Journal of the American Medical Association, vol.276, issue.8, p.649, 1996.
DOI : 10.1001/jama.276.8.649

D. Altman, K. Schulz, D. Moher, M. Egger, F. Davidoff et al., The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration, Annals of Internal Medicine, vol.134, issue.8, pp.663-94, 2001.
DOI : 10.7326/0003-4819-134-8-200104170-00012

C. Begg, M. Cho, S. Eastwood, R. Horton, D. Moher et al., Improving the Quality of Reporting of Randomized Controlled Trials, JAMA, vol.276, issue.8, pp.637-646, 1996.
DOI : 10.1001/jama.1996.03540080059030

T. Chalmers, H. Smith, B. Blackburn, B. Silverman, B. Schroeder et al., A method for assessing the quality of a randomized control trial, Controlled Clinical Trials, vol.2, issue.1, pp.31-49, 1981.
DOI : 10.1016/0197-2456(81)90056-8

D. Altman and C. Doré, Randomisation and baseline comparisons in clinical trials. The Lancet, 20 janv, vol.335, issue.8682, pp.149-53, 1990.

K. Schulz and D. Grimes, Blinding in randomised trials: hiding who got what. The Lancet. 23 févr, pp.696-700, 2002.

M. Vray, D. Girault, N. Hoog-labouret, R. Porcher, and J. Thalabard, M??thodologie des essais cliniques de petits effectifs, Th??rapie, vol.59, issue.3, pp.273-282, 2004.
DOI : 10.2515/therapie:2004054

P. Rothwell, Can overall results of clinical trials be applied to all patients? The Lancet, 24 juin, vol.345, issue.8965, pp.1616-1625, 1995.

J. Mahon, A. Laupacis, A. Donner, and T. Wood, Randomised study of n of 1 trials versus standard practice, BMJ, vol.312, issue.7038, p.1069, 1996.
DOI : 10.1136/bmj.312.7038.1069

P. Rothwell, External validity of randomised controlled trials: « To whom do the results of this trial apply? ». The Lancet. 1 janv, pp.82-93, 2005.

S. Vohra and S. Punja, N-of-1 trials: individualized medication effectiveness tests, Virtual Mentor VM. janv, vol.15, issue.1, pp.42-47, 2013.

G. Bugeja, A. Kumar, and A. Banerjee, Exclusion of elderly people from clinical research: a descriptive study of published reports, BMJ, vol.315, issue.7115, p.1059, 1997.
DOI : 10.1136/bmj.315.7115.1059

R. Kravitz, N. Duan, and J. Braslow, Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages, The Milbank Quarterly, vol.327, issue.6, pp.661-87, 2004.
DOI : 10.1001/jama.266.1.93

T. Sørensen, Which patients may be harmed by good treatments? Lancet. 10 août 1996, pp.351-353

N. Longford, Selection bias and treatment heterogeneity in clinical trials, Statistics in Medicine, vol.47, issue.12, pp.1467-74, 1999.
DOI : 10.1002/(SICI)1097-0258(19990630)18:12<1467::AID-SIM149>3.0.CO;2-H

R. Giugliano, C. Ruff, E. Braunwald, S. Murphy, S. Wiviott et al., Edoxaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.369, issue.22, pp.2093-104, 2013.
DOI : 10.1056/NEJMoa1310907

URL : https://hal.archives-ouvertes.fr/hal-00934699

R. Hayward, D. Kent, S. Vijan, and T. Hofer, Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis, BMC Medical Research Methodology, vol.135, issue.1, p.18, 2006.
DOI : 10.1002/bimj.200510157

D. Kent and R. Hayward, Limitations of Applying Summary Results of Clinical Trials to Individual Patients, JAMA, vol.298, issue.10, pp.1209-1221, 2007.
DOI : 10.1001/jama.298.10.1209

M. Vray, D. Girault, N. Hoog-labouret, R. Porcher, and J. Thalabard, M??thodologie des essais cliniques de petits effectifs, Th??rapie, vol.59, issue.3, pp.273-282, 2004.
DOI : 10.2515/therapie:2004054

G. Guyatt, R. Haynes, and R. Jaeschke, Users' Guides to the Medical Literature, JAMA, vol.284, issue.10, pp.1290-1296, 2000.
DOI : 10.1001/jama.284.10.1290

G. Guyatt, D. Sackett, D. Taylor, J. Ghong, R. Roberts et al., Determining Optimal Therapy ??? Randomized Trials in Individual Patients, New England Journal of Medicine, vol.314, issue.14, pp.889-92, 1986.
DOI : 10.1056/NEJM198604033141406

S. Stoll, V. Roelcke, and H. Raspe, Gibt es eine deutsche Vorgeschichte der Evidenz-basierten Medizin?, DMW - Deutsche Medizinische Wochenschrift, vol.130, issue.30, pp.1781-1785, 1932.
DOI : 10.1055/s-2005-871896

L. Hogben and M. Sim, The Self-Controlled and Self-Recorded Clinical Trial for Low-Grade Morbidity, International Journal of Epidemiology, vol.40, issue.6, pp.1438-54, 2011.
DOI : 10.1093/ije/dyr026

G. Guyatt, D. Sackett, J. Adachi, R. Roberts, J. Chong et al., A clinician's guide for conducting randomized trials in individual patients, CMAJ Can Med Assoc J. 15 sept, vol.139, issue.6, p.497, 1988.

G. Guyatt, A. Heyting, R. Jaeschke, J. Keller, J. Adachi et al., N of 1 randomized trials for investigating new drugs, Controlled Clinical Trials, vol.11, issue.2, pp.88-100, 1990.
DOI : 10.1016/0197-2456(90)90003-K

C. Nikles, P. Glasziou, D. Mar, C. Duggan, C. Mitchell et al., N of 1 trials. Practical tools for medication management, Aust Fam Physician. nov, vol.29, issue.11, pp.1108-1120, 2000.

P. Schluter and R. Ware, Single patient (n-of-1) trials with binary treatment preference, Statistics in Medicine, vol.139, issue.17, pp.2625-2661, 2005.
DOI : 10.1002/sim.2132

J. Bland and D. Altman, Regression towards the mean, BMJ. 4 juin, vol.308, issue.6942, p.1499, 1994.

N. Gabler, N. Duan, S. Vohra, and R. Kravitz, N-of-1 Trials in the Medical Literature, Medical Care, vol.49, issue.8, pp.761-769, 2011.
DOI : 10.1097/MLR.0b013e318215d90d

M. Ulmer, D. Robinaugh, J. Friedberg, S. Lipsitz, and S. Natarajan, Usefulness of a run-in period to reduce drop-outs in a randomized controlled trial of a behavioral intervention, Contemporary Clinical Trials, vol.29, issue.5, pp.705-715, 2008.
DOI : 10.1016/j.cct.2008.04.005

C. Paterson, Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF-36 health survey, BMJ, vol.312, issue.7037, pp.1016-1036, 1996.
DOI : 10.1136/bmj.312.7037.1016

R. Lewis and R. Wears, An introduction to the Bayesian analysis of clinical trials, Annals of Emergency Medicine, vol.22, issue.8, pp.1328-1364, 1993.
DOI : 10.1016/S0196-0644(05)80119-2

D. Wijeysundera, P. Austin, J. Hux, W. Beattie, and A. Laupacis, Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials, Journal of Clinical Epidemiology, vol.62, issue.1, pp.13-21, 2009.
DOI : 10.1016/j.jclinepi.2008.07.006

D. Zucker, C. Schmid, M. Mcintosh, D. Agostino, R. Selker et al., Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment, Journal of Clinical Epidemiology, vol.50, issue.4, pp.401-411, 1997.
DOI : 10.1016/S0895-4356(96)00429-5

C. Nikles, A. Clavarino, D. Mar, and C. , Using n-of-1 trials as a clinical tool to improve prescribing, Br J Gen Pract J R Coll Gen Pract. mars, vol.55, issue.512, pp.175-80, 2005.

S. Brookes, L. Biddle, C. Paterson, G. Woolhead, and P. Dieppe, "Me's me and you's you": Exploring patients' perspectives of single patient (n-of-1) trials in the UK, Trials, vol.42, issue.1, p.10, 2007.
DOI : 10.1016/0895-4356(89)90035-8

R. Griggs, M. Batshaw, M. Dunkle, R. Gopal-srivastava, E. Kaye et al., Clinical research for rare disease: Opportunities, challenges, and solutions, Molecular Genetics and Metabolism, vol.96, issue.1, pp.20-26, 2009.
DOI : 10.1016/j.ymgme.2008.10.003

E. Lillie, B. Patay, J. Diamant, B. Issell, E. Topol et al., The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?, Personalized Medicine, vol.8, issue.2, pp.161-73, 2011.
DOI : 10.2217/pme.11.7

X. Chen and P. Chen, A Comparison of Four Methods for the Analysis of N-of-1 Trials, PLoS ONE, vol.26, issue.2, p.87752, 2014.
DOI : 10.1371/journal.pone.0087752.s004

J. Price, G. Evans, and J. , N-of-1 randomized controlled trials ('N-of-1 trials'): singularly useful in geriatric medicine, Age and Ageing, vol.31, issue.4, pp.227-259, 2002.
DOI : 10.1093/ageing/31.4.227

R. Kravitz, D. Paterniti, M. Hay, S. Subramanian, D. Dean et al., Marketing therapeutic precision: Potential facilitators and barriers to adoption of n-of-1 trials, Contemporary Clinical Trials, vol.30, issue.5, pp.436-481, 2009.
DOI : 10.1016/j.cct.2009.04.001

R. Kravitz, N-of-1 Trials of Expensive Biological Therapies<subtitle>A Third Way?</subtitle>, Archives of Internal Medicine, vol.168, issue.10, p.1030, 2008.
DOI : 10.1001/archinte.168.10.1030

P. Scuffham, J. Nikles, G. Mitchell, M. Yelland, N. Vine et al., Using N-of-1 Trials to Improve Patient Management and Save Costs, Journal of General Internal Medicine, vol.117, issue.6, pp.906-919, 2010.
DOI : 10.1007/s11606-010-1352-7

P. Scuffham, M. Yelland, J. Nikles, E. Pietrzak, and D. Wilkinson, Are N-of-1 Trials an Economically Viable Option to Improve Access to Selected High Cost Medications? The Australian Experience, Value in Health, vol.11, issue.1, pp.97-109, 2008.
DOI : 10.1111/j.1524-4733.2007.00218.x

J. Pope, M. Prashker, and J. Anderson, The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis, J Rheumatol. janv, vol.31, issue.1, pp.140-149, 2004.

M. Armstrong, S. Fox, and C. Marras, Improvement of Apathy After Levofloxacin Treatment, The Neurologist, vol.18, issue.3, pp.146-154, 2012.
DOI : 10.1097/NRL.0b013e318251eb23

C. Nikles, M. Yelland, P. Glasziou, D. Mar, and C. , Do Individualized Medication Effectiveness Tests (N-of-1 Trials) Change Clinical Decisions About Which Drugs to Use for Osteoarthritis and Chronic Pain?, American Journal of Therapeutics, vol.12, issue.1, pp.92-99, 2005.
DOI : 10.1097/00045391-200501000-00012

C. Nikles, G. Mitchell, D. Mar, C. Clavarino, A. Mcnairn et al., An n-of-1 Trial Service in Clinical Practice: Testing the Effectiveness of Stimulants for Attention-Deficit/Hyperactivity Disorder, PEDIATRICS, vol.117, issue.6, pp.2040-2046, 2006.
DOI : 10.1542/peds.2005-1328

B. Smith, S. Appleton, A. Veale, H. Mcelroy, D. Veljkovic et al., Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol, Chronic Respiratory Disease, vol.1, issue.2, pp.63-72, 2004.
DOI : 10.1191/1479972304cd028oa

B. Lashner, S. Hanauer, and M. Silverstein, Testing nicotine gum for ulcerative colitis patients, Digestive Diseases and Sciences, vol.310, issue.7, pp.827-859, 1990.
DOI : 10.1007/BF01536795

D. Goldenberg, M. Mayskiy, C. Mossey, R. Ruthazer, and C. Schmid, A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia, Arthritis & Rheumatism, vol.38, issue.11, pp.1852-1861, 1996.
DOI : 10.1002/art.1780391111

D. Zucker, R. Ruthazer, C. Schmid, J. Feuer, P. Fischer et al., Lessons learned combining N-of-1 trials to assess fibromyalgia therapies, J Rheumatol. oct, vol.33, issue.10, pp.2069-77, 2006.

A. Herrick, Pathogenesis of Raynaud's phenomenon, Rheumatology, vol.44, issue.5, pp.587-96, 2005.
DOI : 10.1093/rheumatology/keh552

J. Cooke and J. Marshall, Mechanisms of Raynaud's disease, Vascular Medicine, vol.10, issue.4, pp.293-307, 2005.
DOI : 10.1191/1358863x05vm639ra

M. Trojanowska, Cellular and molecular aspects of vascular dysfunction in systemic sclerosis Disponible sur, Nat Rev Rheumatol, vol.6, issue.8, 2010.

A. Herrick, Vascular function in systemic sclerosis, Current Opinion in Rheumatology, vol.12, issue.6, pp.527-560, 2000.
DOI : 10.1097/00002281-200011000-00009

H. Maricq, P. Carpentier, M. Weinrich, J. Keil, A. Franco et al., Geographic variation in the prevalence of Raynaud's phenomenon, J Rheumatol. janv, vol.20, issue.1, pp.70-76, 1993.

H. Chifflot, B. Fautrel, C. Sordet, E. Chatelus, and J. Sibilia, Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review, Seminars in Arthritis and Rheumatism, vol.37, issue.4, pp.223-258, 2008.
DOI : 10.1016/j.semarthrit.2007.05.003

Y. Roquelaure, C. Ha, L. Manac-'h, A. Bodin, J. Bodere et al., Risk factors for Raynaud's phenomenon in the workforce, Arthritis Care & Research, vol.52, issue.Suppl 1, pp.898-904, 2012.
DOI : 10.1002/acr.21615

B. Vinjar and M. Stewart, Oral vasodilators for primary Raynaud's phenomenon, Cochrane Database Syst Rev, issue.2, p.6687, 2008.

A. Thompson and J. Pope, Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology. 2 janv, pp.145-50, 2005.

A. Thompson, B. Shea, V. Welch, D. Fenlon, and J. Pope, Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis, Arthritis & Rheumatism, vol.242, issue.8, pp.1841-1848, 2001.
DOI : 10.1002/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8

M. Roustit, M. Hellmann, C. Cracowski, S. Blaise, and J. Cracowski, Sildenafil Increases Digital Skin Blood Flow During All Phases of Local Cooling in Primary Raynaud's Phenomenon, Clinical Pharmacology & Therapeutics, vol.260, issue.5, pp.813-822, 2012.
DOI : 10.1038/clpt.2011.302